Search This Blog

Friday, May 29, 2026

Replimune to resubmit RP1 BLA for advanced melanoma as FDA prioritizes review as urgent

 


  • Resubmission will occur in the coming days after Replimune aligned with the FDA on the application.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)